These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3722135)

  • 21. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled double-blind study of haloperidol versus thioridazine in the treatment of restless mentally subnormal patients. Serum levels and clinical effects.
    Väisänen K; Rimón R; Räisänen P; Viukari M
    Acta Psychiatr Belg; 1979; 79(6):673-85. PubMed ID: 554446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of the therapeutic effects between haloperidol and insulin coma in schizophrenia and optimal blood levels of haloperidol].
    Shu L
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1987 Feb; 20(1):43-8. PubMed ID: 3304870
    [No Abstract]   [Full Text] [Related]  

  • 24. Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study.
    Bigelow LB; Kirch DG; Braun T; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Psychopharmacol Bull; 1985; 21(1):66-8. PubMed ID: 3983341
    [No Abstract]   [Full Text] [Related]  

  • 25. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of classic antipsychotic haloperidol plus the extract of ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia.
    Zhou D; Zhang X; Su J; Nan Z; Cui Y; Liu J; Guan Z; Zhang P; Shen Y
    Chin Med J (Engl); 1999 Dec; 112(12):1093-6. PubMed ID: 11721446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
    J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
    Shvartsburd A; Sajadi C; Morton V; Mirabi M; Gordon J; Smith RC
    J Clin Psychopharmacol; 1984 Aug; 4(4):194-8. PubMed ID: 6470190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluoxetine augmentation of haloperidol in chronic schizophrenia.
    Shim JC; Kelly DL; Kim YH; Yoon YR; Park JH; Shin JG; Conley RR
    J Clin Psychopharmacol; 2003 Oct; 23(5):520-2. PubMed ID: 14520132
    [No Abstract]   [Full Text] [Related]  

  • 31. Plasma haloperidol levels: clinical response and fancy mathematics.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1985 Aug; 42(8):835-8. PubMed ID: 4015328
    [No Abstract]   [Full Text] [Related]  

  • 32. The relationship between plasma haloperidol concentrations and clinical results.
    Palao DJ; Araúxo A; Haro JM; Brunet M; Bernardo M
    Arch Gen Psychiatry; 1996 Dec; 53(12):1167-9. PubMed ID: 8956684
    [No Abstract]   [Full Text] [Related]  

  • 33. Correlation of haloperidol levels between saliva and plasma of acutely ill schizophrenic patients.
    Jain T; Bhandari A; Ram V; Sharma S; Parakh M; Parakh MC
    Clin Biochem; 2011 Jun; 44(8-9):675-80. PubMed ID: 21458435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
    Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
    Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum level of haloperidol and its clinical significance.
    Itoh H; Yagi G; Ohtsuka N; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol; 1980; 4(2):171-83. PubMed ID: 7403350
    [No Abstract]   [Full Text] [Related]  

  • 36. The interpretation of plasma haloperidol concentrations.
    Kirch DG; Bigelow LB; Wyatt RJ
    Arch Gen Psychiatry; 1985 Aug; 42(8):838-40. PubMed ID: 4015329
    [No Abstract]   [Full Text] [Related]  

  • 37. A new approach to dose reduction in chronic schizophrenia.
    Hirschowitz J; Hitzemann R; Burr G; Schwartz A
    Neuropsychopharmacology; 1991 Sep; 5(2):103-13. PubMed ID: 1834073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients.
    Liberman RP; Van Putten T; Marshall BD; Mintz J; Bowen L; Kuehnel TG; Aravagiri M; Marder SR
    Am J Psychiatry; 1994 May; 151(5):756-9. PubMed ID: 8166320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum haloperidol levels of schizophrenics receiving treatment for tuberculosis.
    Takeda M; Nishinuma K; Yamashita S; Matsubayashi T; Tanino S; Nishimura T
    Clin Neuropharmacol; 1986; 9(4):386-97. PubMed ID: 3731135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of dopamine receptor blocking assay with plasma drug levels of haloperidol in schizophrenic patients.
    Kurland AA; Nagaraju A; Hanlon TE; Wilkinson EH; Ng KT
    J Clin Pharmacol; 1981 Jan; 21(1):42-7. PubMed ID: 7217342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.